Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-MID-PAL: Pharmacokinetics of Subcutaneous vs Intravenous Midazolam in Terminally Ill Patients
2025-521082-26-00Phase 2Authorised
- Sponsor
- Akershus University Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of midazolam in cancer (2 arms), sponsored by Akershus University Hospital. Primary endpoint: AUC0-90 of midazolam. Planned start Jun 2025; status: authorised.
02
Drugs
midazolam
03
Conditions
cancer
Beyond the preview
Go deeper on 2025-521082-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521082-26-00.